Overactive bladder (OAB) is a prevalent urological condition often perceived as negligible or non-threatening, leading to its potential links with severe health conditions being overlooked. Notably, the relationship between OAB and cancer remains unexplored. This study endeavors to elucidate the association of OAB with cancer prevalence and mortality risks.

Methods

This study utilized data from the 2007 to 2016 cycles of the National Health and Nutrition Examination Survey (NHANES), incorporating linked mortality data up to December 31, 2019. OAB symptoms were quantified using the modified overactive bladder symptom score (OABSS), with scores ≥ 3 confirming diagnosis. Cancer status was self-reported and further clarified for cancer type. We employed multivariate weighted logistic regression to examine the association between OAB and cancer prevalence, and subgroup analysis to identify variations across demographic and clinical characteristics. Cumulative mortality incidence curves, adjusted via inverse probability weighting, and multivariate Cox regression analysis were utilized to investigate the relationship between OAB and cancer-related mortality.

Results

A total of 20 468 adults aged 20 and older were involved in this study. After adjusting for potential confounders, OAB was positively associated with the risk of cancer (OR = 1.36, 95% CI: 1.18, 1.57). Subgroup analysis revealed significant interactions between OAB and age (P_interaction = 0.001). Survival analysis suggests that OAB was linked to higher all-cause mortality risks exclusively among cancer patients (HR 1.39, 95% CI: 1.17, 1.65) and elevated cancer-specific mortality across the overall population (HR 1.33, 95% CI: 1.03, 1.73).

Conclusion

OAB is associated with the prevalence and mortality of cancer among US adults.

Conflicts of Interest

The authors declare no conflicts of interest.

Open Research

Data Availability Statement

The data sets used and analyzed during this study are available from the National Health and Nutrition Examination Survey (NHANES) database https://www.cdc.gov/nchs/nhanes/index.htm.

Supporting Information

References

1L. Zhang, N. Cai, L. Mo, X. Tian, H. Liu, and B. Yu, “Global Prevalence of Overactive Bladder: A Systematic Review and Meta-Analysis,” International Urogynecology Journal (2025). Epub ahead of print.
10.1007/s00192-024-06029-2
Web of Science® Google Scholar
2B. Peyronnet, E. Mironska, C. Chapple, et al., “A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment,” European Urology 75, no. 6 (2019): 988–1000.
10.1016/j.eururo.2019.02.038
PubMed Web of Science® Google Scholar
3M. Gacci, G. Corona, A. Sebastianelli, et al., “Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-Analysis,” European Urology 70, no. 5 (2016): 788–796.
10.1016/j.eururo.2016.07.007
PubMed Web of Science® Google Scholar
4 The Lancet Public Health, “Inequalities in Cancer: A Major Public Health Concern,” Lancet Public Health 9, no. 3 (2024): e147.
10.1016/S2468-2667(24)00029-X
CAS PubMed Google Scholar
5F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.
10.3322/caac.21834
PubMed Web of Science® Google Scholar
6Y. Ohara, P. Valenzuela, and S. P. Hussain, “The Interactive Role of Inflammatory Mediators and Metabolic Reprogramming in Pancreatic Cancer,” Trends in Cancer 8, no. 7 (2022): 556–569.
10.1016/j.trecan.2022.03.004
CAS PubMed Web of Science® Google Scholar
7L. N. Hsu, J. C. Hu, P. Y. Chen, W. C. Lee, and Y. C. Chuang, “Metabolic Syndrome and Overactive Bladder Syndrome May Share Common Pathophysiologies,” Biomedicine 10, no. 8 (2022): 1957.
CAS Google Scholar
8K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic Syndrome and Risk of Cancer: A Systematic Review and Meta-Analysis,” Diabetes Care 35, no. 11 (2012): 2402–2411.
10.2337/dc12-0336
PubMed Web of Science® Google Scholar
9P. Tyagi, D. Barclay, R. Zamora, et al., “Urine Cytokines Suggest an Inflammatory Response in the Overactive Bladder: A Pilot Study,” International Urology and Nephrology 42, no. 3 (2010): 629–635.
10.1007/s11255-009-9647-5
PubMed Web of Science® Google Scholar
10S. Cohen, D. Janicki-Deverts, and G. E. Miller, “Psychological Stress and Disease,” JAMA 298, no. 14 (2007): 1685–1687.
10.1001/jama.298.14.1685
CAS PubMed Web of Science® Google Scholar
11J. G. Blaivas, G. Panagopoulos, J. P. Weiss, and C. Somaroo, “Validation of the Overactive Bladder Symptom Score,” Journal of Urology 178, no. 2 (2007): 543–547, discussion 547.
10.1016/j.juro.2007.03.133
PubMed Web of Science® Google Scholar
12W. Lin, T. Li, Z. Xu, et al., “Association of Socioeconomic Status and Overactive Bladder in US Adults: A Cross-Sectional Analysis of Nationally Representative Data,” Frontiers in Public Health 12 (2024): 1345866.
10.3389/fpubh.2024.1345866
PubMed Web of Science® Google Scholar
13J. H. Lee, D. Kim, H. J. Kim, et al., “Hepatic Steatosis Index: A Simple Screening Tool Reflecting Nonalcoholic Fatty Liver Disease,” Digestive and Liver Disease 42, no. 7 (2010): 503–508.
10.1016/j.dld.2009.08.002
CAS Web of Science® Google Scholar
14C. Sheng, M. Qiu, T. Zhang, J. Zhang, and H. Gao, “Association Between the American Heart Association's New “Life Essentials 8” Metrics and Urgency Urinary Incontinence and Nocturia,” International Urology and Nephrology 56 (2024): 3519–3527.
10.1007/s11255-024-04133-2
PubMed Web of Science® Google Scholar
15K. Wang and J. Liu, “Positive Association of the Anti-Aging Protein Alpha-Klotho With Insulin Resistance and Its Inverse L-Shaped Relationship With Glycaemic Control in the Middle-Aged and Elderly Population,” Endocrine 86 (2024): 143–155.
10.1007/s12020-024-03874-5
CAS PubMed Web of Science® Google Scholar
16Q. He, L. Wu, C. Deng, et al., “Diabetes Mellitus, Systemic Inflammation and Overactive Bladder,” Frontiers in Endocrinology (Lausanne) 15 (2024): 1386639.
10.3389/fendo.2024.1386639
PubMed Web of Science® Google Scholar
17E. Vitale, A. Rizzo, K. Santa, and E. Jirillo, “Associations Between “Cancer Risk”, “Inflammation” and “Metabolic Syndrome”: A Scoping Review,” Biology 13, no. 5 (2024): 352.
10.3390/biology13050352
CAS PubMed Web of Science® Google Scholar
18H. Lai, V. Gardner, J. Vetter, and G. L. Andriole, “Correlation Between Psychological Stress Levels and the Severity of Overactive Bladder Symptoms,” BMC Urology 15 (2015): 14.
10.1186/s12894-015-0009-6
PubMed Web of Science® Google Scholar
19S. Dai, Y. Mo, Y. Wang, et al., “Chronic Stress Promotes Cancer Development,” Frontiers in Oncology 10 (2020): 1492.
10.3389/fonc.2020.01492
PubMed Web of Science® Google Scholar
20W. C. Lee, S. Lu, C. H. Su, et al., “Tadalafil Ameliorates Chronic Ischemia-Associated Bladder Overactivity in Fructose-Fed Rats by Exerting Pelvic Angiogenesis and Enhancing p-eNOS Expression,” International Journal of Molecular Sciences 26, no. 3 (2025): 1363.
10.3390/ijms26031363
CAS PubMed Web of Science® Google Scholar
21Z. Chen, F. Han, Y. Du, H. Shi, and W. Zhou, “Hypoxic Microenvironment in Cancer: Molecular Mechanisms and Therapeutic Interventions,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 70.
10.1038/s41392-023-01332-8
PubMed Web of Science® Google Scholar
22W. C. Lee, H. R. Yu, Y. L. Tain, K. L. H. Wu, Y. C. Chuang, and J. Y. H. Chan, “Vinpocetine Ameliorates Metabolic-Syndrome-Associated Bladder Overactivity in Fructose-Fed Rats by Restoring Succinate-Modulated cAMP Levels and Exerting Anti-Inflammatory Effects in the Bladder Detrusor Muscle,” Biomedicine 10, no. 11 (2022): 2716.
CAS Google Scholar
23J. Winkler, A. Abisoye-Ogunniyan, K. J. Metcalf, and Z. Werb, “Concepts of Extracellular Matrix Remodelling in Tumour Progression and Metastasis,” Nature Communications 11, no. 1 (2020): 5120.
10.1038/s41467-020-18794-x
CAS PubMed Web of Science® Google Scholar
24A. Bahrami, A. Khalaji, M. Bahri Najafi, et al., “NF-kappaB Pathway and Angiogenesis: Insights Into Colorectal Cancer Development and Therapeutic Targets,” European Journal of Medical Research 29, no. 1 (2024): 610.
10.1186/s40001-024-02168-w
CAS PubMed Web of Science® Google Scholar
25E. W. Lin, T. A. Karakasheva, P. D. Hicks, A. J. Bass, and A. K. Rustgi, “The Tumor Microenvironment in Esophageal Cancer,” Oncogene 35, no. 41 (2016): 5337–5349.
10.1038/onc.2016.34
CAS PubMed Web of Science® Google Scholar
26M. J. Iqbal, A. Kabeer, Z. Abbas, et al., “Interplay of Oxidative Stress, Cellular Communication and Signaling Pathways in Cancer,” Cell Communication and Signaling: CCS 22, no. 1 (2024): 7.
10.1186/s12964-023-01398-5
CAS PubMed Web of Science® Google Scholar
27P. Chen, B. Li, and L. Ou-Yang, “Role of Estrogen Receptors in Health and Disease,” Frontiers in Endocrinology (Lausanne) 13 (2022): 839005.
10.3389/fendo.2022.839005
PubMed Web of Science® Google Scholar
28T. Goto and H. Miyamoto, “The Role of Estrogen Receptors in Urothelial Cancer,” Frontiers in Endocrinology (Lausanne) 12 (2021): 643870.
10.3389/fendo.2021.643870
PubMed Web of Science® Google Scholar
29S. S. Doerstling, C. H. O'Flanagan, and S. D. Hursting, “Obesity and Cancer Metabolism: A Perspective on Interacting Tumor-Intrinsic and Extrinsic Factors,” Frontiers in Oncology 7 (2017): 216.
10.3389/fonc.2017.00216
PubMed Web of Science® Google Scholar
30Z. Lu, J. Zhang, S. Lin, Z. Fan, Z. He, and F. Tang, “Associations Between Overactive Bladder and Sleep Patterns: A Cross-Sectional Study Based on 2007-2014 NHANES,” BMC Urology 23, no. 1 (2023): 184.
10.1186/s12894-023-01329-z
CAS PubMed Web of Science® Google Scholar
31L. Wang, C. Wang, and W. S. Choi, “Use of Melatonin in Cancer Treatment: Where Are we?,” International Journal of Molecular Sciences 23, no. 7 (2022): 3779.
10.3390/ijms23073779
CAS PubMed Web of Science® Google Scholar
32S. M. Szabo, K. L. Gooch, D. R. Walker, K. M. Johnston, and A. S. Wagg, “The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review,” Advances in Therapy 35, no. 11 (2018): 1831–1841.
10.1007/s12325-018-0796-8
PubMed Web of Science® Google Scholar
33D. Kinsey, S. Pretorius, L. Glover, and T. Alexander, “The Psychological Impact of Overactive Bladder: A Systematic Review,” Journal of Health Psychology 21, no. 1 (2016): 69–81.
10.1177/1359105314522084
PubMed Web of Science® Google Scholar
34I. Milsom and D. E. Irwin, “A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results From the EPIC Study,” European Urology Supplements 6, no. 1 (2007): 4–9.
10.1016/j.eursup.2006.10.003
Web of Science® Google Scholar
35W. W. Cheung, N. H. Khan, K. K. Choi, M. H. Bluth, and M. T. Vincent, “Prevalence, Evaluation and Management of Overactive Bladder in Primary Care,” BMC Family Practice 10 (2009): 8.
10.1186/1471-2296-10-8
PubMed Web of Science® Google Scholar
36R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12–49.
10.3322/caac.21820
PubMed Web of Science® Google Scholar

Volume17, Issue4

July 2025

e70018

Overactive Bladder is Positively Associated With the Prevalence and Mortality of Cancer Among US Adults

ABSTRACT

Background

Methods

Results

Conclusion

Conflicts of Interest

Open Research

Data Availability Statement

Supporting Information

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Overactive Bladder is Positively Associated With the Prevalence and Mortality of Cancer Among US Adults

ABSTRACT

Background

Methods

Results

Conclusion

Conflicts of Interest

Open Research

Data Availability Statement

Supporting Information

References

References

Related

Information